TIRZ

Chain: Synthetic 39–amino acid dual GIP & GLP-1 receptor agonist.
Research focus: Mimics incretin hormones to improve insulin sensitivity and support glucose control.
Studies: The SURMOUNT-1 trial (NEJM, 2022) showed significant reductions in body weight and improved metabolic markers over 72 weeks.
Highlights: Investigated for metabolic regulation, weight management, and appetite signaling.
Disclaimer: Intended for research purposes only. Not for human or animal consumption.